Apicus · a field guide for founders

There are 10 ways to fund a startup. Most founders only know 4.

Everyone talks about VC, angels, friends & family, and loans. Almost nobody talks about strategic corporate capital, non-dilutive grants, or revenue-based financing. Explore every path, with the documents, the pitfalls, and the actual people to call.

0 funding paths mapped
0 official YC SAFE variants
0 in non-dilutive SBIR grants
0 minimum dilution required

No. 01 · The landscape

The 10 paths to capital

Every card shows typical check size, how much of your company it costs, and how fast the money lands. Click any card for the deep dive: pitfalls, documents, and who to contact.

No. 02 · The one nobody tells you about

Strategic & corporate capital

Large corporations invest billions into startups every year through corporate venture arms and partnership programs. They bring things a VC never can: distribution, pilot customers, and instant credibility.

Your startup speed · innovation · talent
Capital · pilot deals · distribution · credibility
Innovation · market insight · acquisition option
Corporate partner reach · budget · customers

Why it's underrated

  • A CVC check often comes with a commercial deal attached: a pilot, a co-sell agreement, or marketplace placement worth more than the money.
  • Corporate validation collapses enterprise sales cycles. "Backed by Salesforce Ventures" opens doors cold email never will.
  • Many corporates run partner programs that pay you (cloud credits, co-marketing budgets, paid non-recurring engineering) with zero equity taken.

Watch the fine print

  • Right of first refusal (ROFR) on acquisition can scare off every other buyer. Negotiate it out, or at least down to a notice right.
  • Exclusivity clauses can lock you out of an entire category of customers or partners.
  • Information rights may hand your roadmap to a future competitor. Scope them tightly.

Who writes these checks

Start with the corporate development or CVC arm of companies already adjacent to your product, then work partner programs in parallel. Full contact list in the

No. 03 · Side by side

What each path really costs

Typical ownership given up in a single raise from each source. Bars are representative midpoints; real terms vary with stage, leverage, and negotiation.

The full matrix

SourceTypical checkDilutionSpeed to cashRepaymentBest stage

Speed to cash: five dots means money lands in days; one dot means many months.

No. 04 · How big is "huge"?

Market math: what size means to each investor

"VCs need a huge market" is true but useless, because "huge" is set by fund math: a fund's winners must be able to return the whole fund, so the fund's size dictates the outcome it needs and the outcome dictates the market. A $50M seed fund and a $2B multistage fund are underwriting different companies. The ranges below are directional, but they're the ranges partners actually use.

The fund math, in one line: fund size ÷ ownership at exit = the exit that returns the fund once. A $100M fund holding 10% at exit needs a $1B exit from a single winner just to return the fund once, before fees, so they want each bet to be capable of that alone. Before pitching a fund, run this math on their fund size; it tells you what market story they need to believe.

What each type of investor wants to see

Investor typeTypical fundOutcome they underwriteMarket they wantHow they actually size it
Pre-seed & micro-VC$10M – $75M$250M – $1B exits$500M+ TAM, growingA niche is fine if the wedge credibly expands
Seed funds$50M – $200M$1B+ outcomes$1B+ TAM, $10B preferredBottom-up: real buyers × realistic price
Multistage SaaS / tech$500M – $3B+$10B+ IPO-scale winners$10B+ TAMThe path to $100M+ ARR matters more than the TAM slide
Vertical SaaS specialists$100M – $500M$1B – $5B acquisitions$1B – $5B TAM is acceptableHigh win rate in the vertical plus expansion revenue per customer
Deep tech / frontier$200M – $1BNew categories entirely$10B+ future marketCost curves: what becomes possible when the price drops 10x
Biotech / life sciences$250M – $1B+Approved drugs at scaleIndication-sized: $1B+ peak annual sales, or orphan with pricing powerPatients × price × penetration, per indication
Defense / national security$100M – $1BProgram-of-record revenueBudget lines, not TAM slides: programs measured in $1B+ per yearProcurement budgets and a dual-use commercial market on the side
Consumer$100M – $1BBreakout brands & networks$10B+ categories, 100M+ potential usersFrequency × spend and winner-take-most dynamics
Fintech$100M – $1B+$1B+ outcomesRevenue TAM: take rate × flowsThe classic trap is citing payment volume as your market; they size your cut of it
Climate & industrial$200M – $1.5BInfrastructure-scale companiesTrillion-scale energy and materials marketsMarket size is assumed; unit economics at scale decide everything

Ranges are directional and shift with the market cycle. The invariant: pitch funds whose math your market can satisfy. A vertical product in a $2B niche is a bad pitch to a $2B multistage fund and a great pitch to a vertical specialist.

TAM, SAM, SOM: the three numbers on every market slide

TAMeveryone who could conceivably buy
e.g. $6B
SAMthe slice your product and geography reach today
$2.4B
SOMwhat you can credibly win in 3–5 years
$480M

Investors ignore the TAM headline and sanity-check the SOM, because the SOM is what prices this round. Build all three bottom-up (buyers × price × attainable share) and be ready to defend every factor. A top-down "1% of a $60B market" is the fastest way to lose the room.

No. 05 · Protect the company

The paperwork: SAFEs & legal documents

Y Combinator open-sourced the post-money SAFE (Simple Agreement for Future Equity), the default instrument for early fundraising. There are exactly three official variants, plus an optional side letter. All are free.

1

Valuation Cap, no Discount

The workhorse. Sets a maximum valuation at which the SAFE converts. If you raise your priced round above the cap, the investor converts as if the company were worth the cap, rewarding early risk.

Cap $8M · round at $16M investor converts at ½ the round price
Download from YC ↗
2

Discount, no Valuation Cap

No cap. Instead, the investor converts at a fixed discount (commonly 10–25%) to whatever price the next priced round sets. Simple, but gives the investor no protection against a huge valuation jump.

20% discount · round at $1.00/share investor pays $0.80/share
Download from YC ↗
3

MFN (uncapped, "Most Favored Nation")

No cap, no discount. Instead, if you later issue a SAFE with better terms to anyone else, this investor can adopt those terms. It's what YC itself uses for the $375k portion of its standard deal.

Later SAFE gets a $10M cap MFN holder can claim that cap too
Download from YC ↗

+ Pro Rata Side Letter

Optional add-on giving a SAFE investor the right to buy into your next priced round to maintain their ownership percentage. Pro rata is the most common side letter, not the only one: information rights, major-investor status, and MFN letters circulate too. Keep a register of every letter you sign.

+ Safe User Guide

YC's official PDF walking through conversion math, dilution examples, and when to use each variant. Read it before you sign anything.

Priced round? Use NVCA model docs

When you graduate to a priced equity round, the National Venture Capital Association publishes the industry-standard term sheet, stock purchase agreement, and charter, free at nvca.org ↗.

The unofficial fourth variant

Investors routinely mark up the cap SAFE to add a discount as well; at conversion they take whichever term yields more shares. It isn't one of YC's three official forms, but you will see it. Model both branches before signing.

What a SAFE does before it converts

No maturity date, no interest, no repayment clock. If the company is acquired first, the holder gets the greater of their money back or what conversion would have yielded; in a wind-down they stand ahead of common stock. Otherwise the SAFE simply waits for the priced round.

QSBS: the quiet reason for the C-corp

Qualified Small Business Stock (Section 1202) can exclude $10M+ of capital gains per shareholder on C-corp stock held five years (the 2025 tax law lifted the cap to $15M with a tiered 3-to-5-year schedule for new issuances). SAFEs generally don't start the clock until they convert into stock. Raise it with a tax advisor at formation, not at exit.

What about a pre-money SAFE?

You don't need one. The pre-money SAFE was YC's original 2013 form: ownership couldn't be known until the priced round and dilution from stacking was shared with earlier investors. YC retired it in 2018 and the market standardized on post-money. You'll still meet pre-money SAFEs in older cap tables and the conversion math differs, so always check which form you're holding.

Post-money vs. pre-money matters. YC's current SAFEs are post-money: each SAFE's ownership is calculated after all SAFEs convert, so stacking many SAFEs dilutes founders, not earlier SAFE holders. Model your cap table before every signature. A spreadsheet now beats a lawyer's invoice later.

Go deeper · Chapter No. 06

The full document library

The SAFE is one page of the paper trail. Formation docs, convertible notes, KISS, the NVCA priced-round stack, and the paperwork for all ten funding paths.

No. 06 · Stay legal

Securities law: the rules around the raise

Every check you cash is a sale of securities and it's legal only because an exemption makes it legal. Exemptions come with conditions and the conditions are where founders get hurt. Know which one your raise relies on before the first wire lands.

The exemption map

ExemptionRaise capWho can investCan you advertise?Filings
Rule 506(b)No capAccredited investors, plus up to 35 sophisticated non-accreditedno public solicitationForm D within 15 days
Rule 506(c)No capAccredited only, verified: tax documents, a CPA letter, or (per 2025 SEC guidance) a high minimum investment with written representationsyes, freelyForm D within 15 days
Reg CF$5M per 12 monthsAnyone through a registered funding portal, subject to per-investor limitslimited: testing the waters, then tombstone adsForm C, then annual reports
Reg A+ (Tier 2)$75M per 12 monthsAnyone, with investment limits for non-accredited buyersyes, once qualifiedForm 1-A, ongoing reports

Most quiet SAFE rounds are 506(b) by default. The official rules live at the SEC's exempt offerings guide; state "blue sky" notice filings usually follow the federal ones. The tiniest friends-and-family rounds often rest informally on the statutory Section 4(a)(2) private-offering exemption; Reg D is its safe-harbor version, which is why lawyers steer you onto it.

The compliance basics

  • Pick the exemption before the raise, not after. A quiet round is 506(b); the moment you want to talk publicly, you need 506(c) and accreditation verification.
  • File Form D within 15 days of the first sale: a short public notice, free, no SEC review, filed through EDGAR, then the state notices.
  • Paper every investor. Accredited questionnaires collected before the wire, not chased afterward.
  • Get a 409A valuation before granting options. Mispriced options are a tax problem for your employees, courtesy of you.

The traps

  • Tweeting the raise. A public "we're raising!" under 506(b) is general solicitation and can void the exemption for the whole round.
  • Paying finders a cut. Success fees to unregistered intermediaries for raising money violate broker-dealer rules; deals have unwound over it.
  • Casual non-accredited checks. Your aunt's $10k is the same securities law as a fund's $1M. Count and document every exception.
  • Treating the exemption as cover. Anti-fraud liability applies to every claim in your deck regardless of exemption. Optimism is legal; misstatement is not.

Who counts as accredited

Individuals with $200k income ($300k with a spouse) in each of the last two years, or $1M net worth excluding the primary residence, plus holders of certain securities licenses. "Sophisticated" (the 506(b) non-accredited allowance) means capable of evaluating the risk; document why you believed it.

Options need their own exemption

Employee and advisor option grants rely on Rule 701, not Reg D; it has its own dollar caps and disclosure thresholds. And before granting anything, get a 409A valuation: the independent appraisal that sets a defensible strike price.

Bad-actor disqualification

Rule 506(d): if a covered person (founders, major shareholders, certain promoters) has a disqualifying securities event, the exemption is void for the entire raise. Run the check before you take money with them attached.

Exemptions excuse registration, not dishonesty. Rule 10b-5 anti-fraud liability follows every number and claim you put in front of an investor. When in doubt about which exemption fits or what you can say publicly, that's the moment for an hour of securities counsel and it's the cheapest hour you'll buy all year.

No. 07 · Before you sign anything

Five golden rules of raising

  1. 01

    Paper every dollar, even Mom's.

    A handshake with family is still a securities transaction. Use a SAFE or promissory note for every check, no matter who writes it.

  2. 02

    Dilution compounds. Model it.

    7% to an accelerator plus 20% at seed plus 20% at Series A leaves founders around 60%; the option-pool top-ups investors require (created pre-money, so out of your side of the table) push it under 50%. Run the math on every stack of SAFEs before signing the next one.

  3. 03

    The cheapest money is revenue.

    Exhaust non-dilutive options first: customers, grants, partner programs. Equity sold at your weakest moment is the most expensive capital you'll ever take.

  4. 04

    Terms beat valuation.

    A clean $8M round beats a $12M round carrying a 2× liquidation preference, board control, or a ROFR. Ugly terms follow you into every future round.

  5. 05

    Pick investors like co-founders.

    You can fire an employee. You can't fire your cap table. Reference-check every investor with founders they've backed, especially the failed ones.

Next chapter · No. 02

Intellectual property in the US

Own what you build: patents, trademarks, copyright, and trade secrets, plus the clocks already ticking.